Related Experiment Videos
A pharmacological study of cefaclor in the newborn infant
Current Medical Research and Opinion
|January 1, 1981
Insights
Cefaclor absorption and excretion were evaluated in 10 newborn infants. This cephalosporin antibiotic demonstrated good absorption and tolerability in neonates, achieving peak serum concentrations rapidly after oral administration.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Neonates often require antibiotic treatment for infections.
- Understanding drug pharmacokinetics in newborns is crucial for safe and effective therapy.
- Cephalosporins are commonly used antibiotics, but their use in neonates requires specific pharmacokinetic data.
Purpose of the Study:
- To investigate the absorption and excretion of cefaclor in newborn infants.
- To determine the pharmacokinetic profile of cefaclor in this vulnerable population.
- To assess the safety and tolerability of cefaclor in neonates.
Main Methods:
- A study involving 10 newborn infants.
- Oral administration of cefaclor at a dose of 7.5 mg/kg.
- Measurement of serum cefaclor concentrations over time.
Main Results:
- A mean peak serum concentration of 7.7 microgram/ml was observed.
- Peak serum concentrations were achieved approximately 1 hour post-administration.
- The drug was found to be well absorbed and tolerated.
Conclusions:
- Cefaclor exhibits favorable absorption characteristics in newborn infants.
- The pharmacokinetic profile suggests suitability for therapeutic use in neonates.
- Cefaclor is a well-tolerated cephalosporin option for treating infections in newborn infants.
Abstract:
The absorption and excretion of cefaclor were studied in 10 newborn infants. A mean peak serum concentration of 7.7 microgram/ml was achieved at 1 hour after an oral dose of 7.5 mg/kg. It is concluded that cefaclor is a well absorbed and tolerated cephalosporin for use in newborn infants.